Guidelines for EUFMD Implementation

Guidelines for EUFMD Implementation

No country is immune to the problems associated with counterfeit medicines. Across the planet, governments are enforcing new regulations and directives to counter the threat of illegal pharmaceuticals to public health and safety.

In this report, ACG examines the EU’s Falsified Medicines Directive – due to be rolled out on February 9 next year.

This paper outlines the insights ACG have gained from their experience in Track & Trace implementation, highlights the challenges faced by pharmaceutical companies across the EU, and posits potential methods of overcoming them. With awareness of counterfeiting increasing, the pharmaceutical industry should be agile in the coming months, and learn to consider regulations as obligations in the years to come.


Please note: That all fields marked with an asterisk (*) are required.